Katia Schlienger

9.6k citations

52 papers · 7.3k indexed · 4 hit papers · h-index 25

Impact in

Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- PARP inhibition in cancer therapy

Papers in

Virology 12
- HIV Research and Treatment 8
Immunology 18
- Immune Cell Function and Interaction 12
- Immunotherapy and Immune Responses 12
- T-cell and B-cell Immunology 9

Co-authors: Stephen C. Rubin George Coukos Carl H. June José R. Conejo-García Dionyssios Katsaros M Massobrio Phyllis A. Gimotty Heidi J. Gray
Journals: Journal of Clinical Oncology (9 papers)Annals of Oncology (8 papers)The Journal of Immunology (5 papers)Vaccine (4 papers)Clinical and Vaccine Immunology (2 papers)
Partner nations: United States France Italy

In The Last Decade

Katia Schlienger

51 papers receiving 7.2k citations

Hit Papers

align trajectories log scale

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer 2019 · 1.5k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 New England Journal of Medicine
2003 New England Journal of Medicine
2002 The Journal of Immunology
2001 PubMed

Peers

Countries citing papers authored by Katia Schlienger

Since Specialization

Citations

This map shows the geographic impact of Katia Schlienger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katia Schlienger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katia Schlienger more than expected).

Fields of papers citing papers by Katia Schlienger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katia Schlienger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katia Schlienger. The network helps show where Katia Schlienger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Katia Schlienger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katia Schlienger Line = papers co-authored together Katia Schlienger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer Annals of Oncology ·Lisle M. Nabell, Alan L. Ho, Marshall R. Posner, Andrew Butler, Ayelén Ledesma, Stuart J. Wong, Jiaxin Niu, Alexander T. Pearson, Douglas Laux, Douglas R. Adkins, Maria Sternemann, Ari J. Rosenberg, Debra L. Richardson, W. Douglas Wong, B C Vishwas, Kianoosh Katchar, Qing Xin, Wendy Vanesa Ricardo Benitez, Katia Schlienger, David G. Pfister	2023	3
2	Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform Frontiers in Oncology ·Henning Lauterbach, Sarah Schmidt, みのり星川, Xiaoping Qing, Wendy Vanesa Ricardo Benitez, P. Infelise, Katia Schlienger, Ursula Berka, Yang XianJin, R. Rodriguez, Karel Složil, P. Khulová, Daniel D. Pinschewer, Igor Matushansky, Klaus K. Orlinger	2021	15
3	Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer New England Journal of Medicine ·Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Vitaly Ryu, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler Hit paper breakdown →	2019	1468
4	Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids Vaccine ·C.G. Kim, Janie Parrino, Rahminah Rahminah, Jabez B. Greenhalgh, Jon E. Stek, Kathleen Coll, Shu‐Chih Su, Jin Xu, Xiaoming Li, Katia Schlienger, Jeffrey L. Silber	2015	26
5	Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age Vaccine ·Choi Gang Won, Joep M. A. Lange, Stephen K. Tyring, Jiraporn Thamniamin, Auni Syamimi, Gregory A. Poland, Myron J. Levin, A. Soria, Kotaro Eguchi, Jianjun Li, Jeffrey G. Smith, Michael J. Caulfield, Jon E. Stek, Ivan S. F. Chan, Rupert Vessey, F. Schödel, Paula W. Annunziato, Katia Schlienger, Jeffrey L. Silber	2011	50
6	Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster Vaccine ·John Raphael B. Cruz, Stephen K. Tyring, Myron J. Levin, Janie Parrino, Xiaoming Li, Kathleen Coll, Jon E. Stek, Katia Schlienger, Ivan S. F. Chan, Jeffrey L. Silber	2010	51
7	Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older Clinical and Vaccine Immunology ·Santosh Sutradhar, L. Godley, Katia Schlienger, Jon E. Stek, Jin Xu, Ivan S. F. Chan, Jeffrey L. Silber	2009	25
8	Immunogenicity, Kinetics of VZV-Specific CD4+ T-cell γ-IFN Production and Safety of a Live Attenuated Oka/Merck Zoster Vaccine in Healthy Adults ≥ 60 Years of Age Katia Schlienger	2006	4
9	Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults Vaccine ·王良玉, Y. Kim, Manuel Guzmán, Jaynier Moya, (unknown), イシハラカズナリ, Poorva Dige, Daniel J. Sepe, Katia Schlienger, I. S. F. Chan, Jerald Sadoff, F. Schödel, Jeffrey L. Silber	2006	33
10	Extensive Replicative Capacity of Human Central Memory T Cells The Journal of Immunology ·Marcela V. Maus, Birgit Kovacs, William W. Kwok, Gerald T. Nepom, Katia Schlienger, James L. Riley, David Allman, Terri H. Finkel, Carl H. June	2004	33
11	A Tumor-Associated Glycoprotein That Blocks MHC Class II-Dependent Antigen Presentation by Dendritic Cells The Journal of Immunology ·Ralf Gutzmer, Wei Li, Shaheen S. Sutterwala, Maria P. Lemos, JI Elizalde, Sandra Leitner, Edward M. Behrens, Susan Mathilda Pretorius, Katia Schlienger, Terri M. Laufer, Stephen L. Eck, Michael S. Marks	2004	20
12	Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4+ T cells to HIV-infected persons Clinical Immunology ·Wendy B. Bernstein, Josephine H. Cox, Naomi Aronson, LaRee Tracy, Katia Schlienger, Silvia Ratto‐Kim, Robin P. Garner, Julio Cotte, Zhaohui Zheng, Lena E. Winestone, Jannez Marianne, J.-C. Trama, Mark Connors, Deborah L. Birx, Richard G. Carroll, Bruce L. Levine	2004	24
13	Decline in Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity with Increasing Age and Boosting with a High‐Dose VZV Vaccine The Journal of Infectious Diseases ·Myron J. Levin, Jeffrey G. Smith, Robin M. Kaufhold, 山内祐平, Anthony Hayward, Christina Y. Chan, Ivan S. F. Chan, Daniel J. Sepe, William Yang Wang, Paul M. Keller, Alan Shaw, Jeffrey L. Silber, Katia Schlienger, Kotaro Eguchi, S. J. RUPERT VESSEY, Michael J. Caulfield	2003	233
14	Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation The Journal of Immunology ·Edward Y. Woo, Heidi Yeh, Christina Chu, Katia Schlienger, Richard G. Carroll, James L. Riley, Larry R. Kaiser, Carl H. June Hit paper breakdown →	2002	549
15	Tumor-Associated Macrophages as a Source of Functional Dendritic Cells in Ovarian Cancer Patients Clinical Immunology ·Christina Chu, Edward Y. Woo, 장동호, Stephen C. Rubin, Carl H. June, Richard G. Carroll, Katia Schlienger	2002	14
16	Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection Nature Medicine ·Bruce L. Levine, Wendy B. Bernstein, Naomi Aronson, Katia Schlienger, Julio Cotte, M. J. Laires, Damin Du, Silvia Ratto‐Kim, Deborah L. Birx, Carolyn M. Steffens, Alan Landay, Richard G. Carroll, Carl H. June	2002	141
17	A Role for CD40-CD40 Ligand Interactions in the Generation of Type 1 Cytokine Responses in Human Leprosy The Journal of Immunology ·Paul S. Yamauchi, 刘立权, Koichi Uyemura, Jenny Kim, Peter A. Sieling, Yu-Shiuan Lin, Hans D. Brightbill, Katia Schlienger, Thomas H. Rea, Robert L. Modlin	2000	44
18	B7-1, But Not CD28, Is Crucial for the Maintenance of the CD4+ T Cell Responses in Human Leprosy The Journal of Immunology ·Katia Schlienger, Koichi Uyemura, D. Jullien, Peter A. Sieling, Thomas H. Rea, P S Linsley, Robert L. Modlin	1998	18
19	Immunogenicity of Hybrid Hepatitis B Surface Antigen Particles International Reviews of Immunology ·M Mancini, Katia Schlienger, Pierre Tiollais, Marie‐Laure Michel	1994	4
20	Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes Research in Virology ·Marie‐Laure Michel, M Mancini, Katia Schlienger, Pierre Tiollais	1993	18

About Katia Schlienger

Katia Schlienger is a scholar working on Virology, Immunology, Oncology, Epidemiology and Infectious Diseases, having authored 52 papers that have together received 7.3k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (12 papers), Immunotherapy and Immune Responses (12 papers), PARP inhibition in cancer therapy (10 papers), Herpesvirus Infections and Treatments (9 papers), T-cell and B-cell Immunology (9 papers), HIV Research and Treatment (8 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Virus-based gene therapy research (6 papers). The work is most often cited by research in Immunology (3.9k citations), Oncology (4.4k citations), Cancer Research (1.0k citations), Reproductive Medicine (547 citations) and Virology (265 citations). Katia Schlienger has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Stephen C. Rubin, George Coukos, Carl H. June, José R. Conejo-García, Dionyssios Katsaros, M Massobrio, Phyllis A. Gimotty, Heidi J. Gray, Michael Liebman and G. Regnani. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Immunology, Vaccine and Clinical and Vaccine Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact